S. Renner

发表

Sensitization to Aspergillus fumigatus and lung function in children with cystic fibrosis.

D. Koller, M. Götz, T. Frischer, 1997, American journal of respiratory and critical care medicine.

Differential expression of IL-33 and HMGB1 in the lungs of stable cystic fibrosis patients

B. Ghanim, C. Akdis, W. Klepetko, 2014, European Respiratory Journal.

Estimating the age of p.(Phe508del) with family studies of geographically distinct European populations and the early spread of cystic fibrosis

E. Génin, M. Macek, C. Férec, 2018, European Journal of Human Genetics.

Early detection of lung function decrements in children and adolescents with cystic fibrosis using new reference values

Z. Szépfalusi, A. Zacharasiewicz, T. Frischer, 2017, Wiener klinische Wochenschrift.

Update on Respiratory Fungal Infections in Cystic Fibrosis Lung Disease and after Lung Transplantation

P. Jaksch, S. Renner, E. Dehlink, 2020, Journal of fungi.

Successful implementation of infection control strategies prevents P. aeruginosa transmission among cystic fibrosis patients inside the hospital

E. Presterl, O. Assadian, D. Mitteregger, 2014, GMS hygiene and infection control.

Effects of long-term oral beta-carotene supplementation on lipid peroxidation in patients with cystic fibrosis.

I. Elmadfa, I. Eichler, S. Renner, 1998, International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition.

Cystic Fibrosis Newborn Screening in Austria Using PAP and the Numeric Product of PAP and IRT Concentrations as Second-Tier Parameters

E. Eber, J. Riedler, A. Zacharasiewicz, 2021, Diagnostics.

A Th17- and Th2-skewed cytokine profile in cystic fibrosis lungs represents a potential risk factor for Pseudomonas aeruginosa infection.

C. Akdis, P. Jaksch, W. Klepetko, 2013, American journal of respiratory and critical care medicine.

Effects of β-carotene supplementation for six months on clinical and laboratory parameters in patients with cystic fibrosis

I. Elmadfa, T. Frischer, S. Lehr, 2001, Thorax.

ects of â-carotene supplementation for six months on clinical and laboratory parameters in patients with cystic fibrosis

I. Elmadfa, T. Frischer, S. Lehr, 2000 .

Long-Term Oral β-Carotene Supplementation in Patients with Cystic Fibrosis – Effects on Antioxidative Status and Pulmonary Function

I. Elmadfa, I. Eichler, S. Renner, 2000, Annals of Nutrition and Metabolism.

Estimating the age of p.(Phe508del) with family studies of geographically distinct European populations and the early spread of cystic fibrosis

E. Génin, M. Macek, C. Férec, 2018, European Journal of Human Genetics.

Case Report: Maintenance of Desensitization to Nebulized Colomycin Over 10 Years

Z. Szépfalusi, S. Renner, J. Sieber, 2021, Frontiers in Pediatrics.

Cystic fibrosis in Austria

E. Eber, J. Riedler, A. Zacharasiewicz, 2017, Wiener klinische Wochenschrift.

Aspergillus fumigatus-specific immunoglobulin levels in BALF of CF patients

R. Crameri, Z. Szépfalusi, K. Schmidthaler, 2017, ERJ Open Research.

S3-Leitlinie: Lungenerkrankung bei Mukoviszidose – Modul 2: Diagnostik und Therapie bei der chronischen Infektion mit Pseudomonas aeruginosa

I. Baumann, E. Rietschel, A. Koitschev, 2018, Pneumologie.

S3-Leitlinie: Lungenerkrankung bei Mukoviszidose – Modul 2: Diagnostik und Therapie bei der chronischen Infektion mit Pseudomonas aeruginosa

E. Rietschel, A. Koitschev, H. Sitter, 2018, Pneumologie.